Here are three that failed:
- AstraZeneca’s Calquence — The drugmaker tested its blood cancer drug, Calquence, to see whether it could help hospitalized COVID-19 patients recover. A phase 2 trial showed the drug didn’t result in fewer deaths or respiratory failures.
- Novartis’ Ilaris — Novartis tested its arthritis drug Ilaris to see whether it could improve survival rates of COVID-19 patients. Clinical trials found the drug didn’t show any benefit for the patients.
- Sanofi & Regeneron’s Kevzara — The drugmakers’ rheumatoid arthritis drug Kevzara was tested to see its anti-inflammatory qualities would help COVID-19 patients, but the drug didn’t significantly shorten patients’ hospital stays in a study of 420 people.
Several drugs are still in clinical trials testing their benefit against the virus, including an inhaled version of interferon, a drug commonly used to treat multiple sclerosis; AbbVie’s rheumatoid arthritis drug Humira; and Eli Lilly’s Olumiant, another rheumatoid arthritis drug.
More articles on pharmacy:
Pfizer says its COVID-19 vaccine is 95% effective
What Amazon’s online pharmacy announcement did to CVS, Walgreens and Rite Aid stock
Data on emergency approval of COVID-19 drugs, vaccines to be made public
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
